# South America Gene Therapy Market > South America Gene Therapy Market Research Report: Size, Share, Trend Analysis By Therapeutic Area (Oncology, Genetic Disorders, Infectious Diseases, Cardiovascular Diseases, Neurological Disorders), By Technology (Viral Vectors, CRISPR, Gene Editing, RNA Therapy, Non-Viral Methods), By Applications (Research, Clinical, Commercial), By Route of Administration (Intravenous, Intramuscular, Intradermal, Intrathecal, Oral) and By Regional (Brazil, Mexico, Argentina, Rest of South America)- Growth Outlook & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 3.73% - **2024:** $ 612 Million - **2025:** $ 634.83 Million - **2035:** $ 916 Million - **Key Players:** Novartis (CH), Gilead Sciences (US), Sangamo Therapeutics (US), Bluebird Bio (US), Spark Therapeutics (US), CRISPR Therapeutics (CH), Bristol-Myers Squibb (US), Roche (CH), AstraZeneca (GB) **Report ID:** MRFR/Pharma/51504-HCR · **Pages:** 200 · **Author:** Nidhi Mandole & Rahul Gotadki · **Last Updated:** February 06, 2026 **URL:** https://www.marketresearchfuture.com/reports/south-america-gene-therapy-market-53265 --- ## Market Summary ## **South America Gene Therapy Market Overview** As per MRFR analysis, the South America Gene Therapy Market Size was estimated at 645 (USD Million) in 2024.The South America Gene Therapy Market Industry is expected to grow from 800(USD Million) in 2025 to 3,000 (USD Million) by 2035. The South America Gene Therapy Market CAGR (growth rate) is expected to be around 12.768% during the forecast period (2025 - 2035) **Key South America Gene Therapy Market Trends Highlighted** The South America Gene Therapy Market is experiencing significant growth driven by advancements in biotechnology and increasing investments in research and development. Governments in countries like Brazil and Argentina are actively promoting initiatives to support life sciences and biotechnology sectors, which are crucial for gene therapy advancements. The regulatory environment in South America is gradually evolving, with clearer guidelines being established to streamline the approval process for gene therapies.  This creates opportunities for companies to introduce innovative treatments more efficiently, addressing unmet medical needs. Recent trends show a surge in collaboration between academic institutions and biotech firms in South America, fostering innovative solutions in gene therapy.Increased focus on personalized medicine and targeted therapies is also shaping the market, as healthcare providers look for more effective ways to treat genetic disorders, such as hemophilia and spinal muscular atrophy, which are prevalent in the region.  Healthcare accessibility is a critical driver; initiatives to enhance awareness about genetic disorders and their treatments are being bolstered by partnerships between public health organizations and private entities. Furthermore, countries in South America are investing in public health education and the training of healthcare professionals about gene therapies, promoting their use in clinical settings. The evolving landscape of healthcare and biotechnology holds substantial opportunities for the growth of the gene therapy market in South America, making it a crucial focus area for stakeholders in the life sciences sector. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review **South America Gene Therapy Market Drivers** **Rising Prevalence of Genetic Disorders** The prevalence of genetic disorders, including rare diseases, is on the rise in South America, providing a robust driver for the South America Gene Therapy Market Industry. According to the Brazilian Ministry of Health, around 13% of the population is affected by some form of genetic condition, with figures indicating that approximately 1 in 4,000 births results in a neonate with a genetic disorder.  The increasing focus on addressing these conditions through innovative therapies, such as gene therapy, is supported by organizations like the Brazilian Society of Genetics, which advocates research and the development of new treatment options.In addition, government aid is expected to increase investment in gene therapy, thereby improving the overall market. **Advancements in Research and Development** The South America Gene Therapy Market Industry is being driven by significant advancements in Research and Development (R&D) capabilities, particularly within local biotechnology firms and universities. For instance, Argentina has developed a strategic plan to invest in biotechnology, with projected R&D spending rising by over 15% annually for the next five years.  This academic-industry collaboration fosters innovation and the development of novel gene therapies, supported by institutions like the National Agency for Industrial Development.By creating an ecosystem that encourages new treatments, access to gene therapy in South America is expected to expand, leading to notable market growth. **Supportive Government Policies** Government policies in South American countries are becoming increasingly supportive of gene therapy advancements, acting as a catalyst for growth in the South America Gene Therapy Market Industry. Countries like Brazil and Colombia have established national health policies that promote the development and regulation of cutting-edge therapies. The Brazilian National Health Surveillance Agency has implemented fast-track approval processes for innovative treatments, significantly reducing the time required for market entry.Such initiatives have the potential to attract investments from global pharmaceutical companies and boost local research initiatives, directly impacting the expansion of gene therapies in the region. **Increased Funding and Investments** The influx of funding and investment in the biotechnology sector is a crucial driver for the growth of the South America Gene Therapy Market Industry. Reports indicate that venture capital investment in South American biotechnology firms has surged, amounting to more than 200 million USD in just the past two years, largely focused on gene therapies and genomics. Furthermore, organizations such as the Latin American Biotech Association are facilitating partnerships and collaborations between startups and investors. This financial backing is essential for the development and commercialization of gene therapies tailored to the specific needs of South American populations, thereby stimulating market growth. **South America Gene Therapy Market Segment Insights** **Gene Therapy Market Therapeutic Area Insights** The Therapeutic Area segment of the South America Gene Therapy Market is experiencing notable advancements and growth, driven by increasing healthcare needs and a growing understanding of gene-editing technologies. Among the key focus areas, oncology stands out due to its significant burden on public health and the potential for innovative gene therapies to provide new treatment avenues for cancer patients. Genetic disorders are also a major contributor, as the prevalence of these conditions calls for effective therapies that can address the underlying genetic causes, making gene therapy vital for enhancing patient outcomes in this area. Infectious diseases have seen an increase in interest, especially given recent global health challenges, highlighting the need for novel therapeutic strategies to tackle viral infections and other pathogens through gene-modifying technologies. Furthermore, cardiovascular diseases represent a leading cause of morbidity and mortality in South America, where gene therapies might offer a cutting-edge approach to address genetic predispositions and restore cardiovascular health.  Neurological disorders also play a crucial role, as there is a pressing demand for treatments that can repair or replace damaged neural tissues, providing hope for conditions previously deemed untreatable.Given these dynamics, the Therapeutic Area segment is not only growing but is also positioning itself as a cornerstone of the South America Gene Therapy Market, promising advancements that aim to improve health outcomes across diverse patient groups. Emphasizing the importance of Research and Development activities in these specific therapeutic areas will be crucial in enhancing clinical outcomes and expanding the reach of gene therapies throughout the region.  The market's future looks lucrative as collaboration between the public and private sectors encourages innovation and accelerates the development of solutions that cater to the unique health challenges faced by the South American population. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review **Gene Therapy Market Technology Insights** The Technology segment of the South America Gene Therapy Market showcases diverse methodologies crucial for advancing therapeutic solutions. Viral Vectors are among the most common tools utilized for gene delivery due to their efficiency in transfecting cells. Meanwhile, CRISPR technology has gained momentum for its precision and versatility in gene editing, making it a prominent focus for Research and Development activities. Gene Editing methods are significant for their potential to correct genetic disorders at a molecular level, offering new treatment avenues.RNA Therapy presents innovative approaches for regulating gene expression, emphasizing its importance in addressing various health conditions.  Non-Viral Methods are becoming increasingly vital as they provide safer alternatives for gene transfer, widening the scope of gene therapy applications. The growth of these technologies is driven by rising investments in biotech and ongoing collaborations between academic and clinical entities in South America, positioning the region as a key player in global gene therapy advancements. As the South America Gene Therapy Market evolves, these technological advancements are expected to redefine treatment paradigms across multiple therapeutic areas. **Gene Therapy Market Application Insights** The South America Gene Therapy Market is witnessing notable growth, particularly within the Application segment, which comprises Research, Clinical, and Commercial applications. Research plays a crucial role in advancing gene therapy techniques, driving innovation, and enhancing our understanding of genetic disorders. The Clinical application is significantly important, as it lays the groundwork for translating research discoveries into viable treatment options for patients, ultimately improving healthcare outcomes. Meanwhile, the Commercial aspect focuses on the marketability and accessibility of gene therapies in South America, which is becoming increasingly significant due to rising healthcare investments and supportive regulatory frameworks in the region. These elements contribute to the market's expansion by fostering collaboration among biotechnology firms, academic institutions, and governmental entities. Challenges such as regulatory hurdles and high development costs persist; however, the increasing prevalence of genetic disorders offers significant opportunities for growth. Overall, the segmentation within the Application category supports a dynamic and responsive approach to addressing the unique healthcare needs of the South American population, positioning the market for sustained development in the coming years. **Gene Therapy Market Route of Administration Insights** The Route of Administration segment in the South America Gene Therapy Market plays a pivotal role in the delivery and effectiveness of therapeutic solutions. Various methodologies, such as Intravenous, Intramuscular, Intradermal, Intrathecal, and Oral administration routes, cater to diverse therapeutic needs for genetic disorders prevalent in the region. Intravenous administration is commonly utilized due to its rapid systemic distribution, crucial for treating severe conditions. Meanwhile, Intramuscular and Intradermal routes are gaining traction for localized delivery and minimizing systemic exposure.Intrathecal administration is particularly significant for central nervous system-targeting therapies, addressing neurological conditions, which are notably relevant in South America considering the rising incidence of such disorders.  The Oral route, while less common in gene therapy, presents an interesting avenue for patient compliance and comfort. The overall dynamics of the South America Gene Therapy Market revenue influenced by the evolving preferences for these routes, each offering unique advantages to patients and healthcare professionals alike.As the market grows, these administration routes will continue to shape therapeutic protocols, driven by advancements in technology and increasing investments in healthcare infrastructure. The South America Gene Therapy Market statistics reflect a growing recognition of these methods as critical components in the development of effective gene therapies aimed at improving patient outcomes. **Gene Therapy Market Regional Insights** The South America Gene Therapy Market represents a burgeoning field within the healthcare industry, reflecting significant advancements in the treatment of genetic disorders. Brazil stands out as a crucial player in this market due to its large population and expanding healthcare infrastructure, showing a strong inclination towards innovative therapies. Meanwhile, Mexico's growing focus on biotechnology and research capabilities contributes positively to its gene therapy landscape.  Argentina showcases potential with government-supported initiatives aimed at fostering biotechnology development, which enhances its role in the gene therapy domain.On the other hand, the Rest of South America is catching up, driven by an increasing awareness of genetic treatments and supportive regulatory frameworks. The market dynamics within these regions reflect rising demand for personalized medicine, fueled by a growing prevalence of genetic diseases and increased investment in research and development.  Overall, the South America Gene Therapy Market segmentation illustrates a landscape ripe with opportunities, driven by innovations and an escalating need for effective treatments across various countries in the region. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review **South America Gene Therapy Market Key Players and Competitive Insights** The South America Gene Therapy Market is a dynamic and rapidly evolving sector characterized by significant growth potential driven by advancements in biotechnology and an increasing focus on personalized medicine. The competitive landscape is marked by a mix of established pharmaceutical giants and emerging biotech firms that are actively investing in innovative therapies to address various genetic disorders and chronic diseases prevalent in the region. A key characteristic of this market is the strong emphasis on research and development, with companies striving to leverage cutting-edge technology to enhance therapy efficacy and safety.  The competition is further intensified by collaborations and partnerships aimed at accelerating product development and improving access to novel treatments for patients across South America.Amgen has established a notable presence in the South America Gene Therapy Market, leveraging its extensive expertise in biotechnology and commitment to innovative therapeutic solutions. The company’s strengths lie in its robust research framework and a portfolio of advanced therapies that cater to unmet medical needs in genetic diseases. Amgen's focus on developing gene therapies that demonstrate significant improvements in patient outcomes has positioned it as a key player in the market.  The company has also made strategic investments in local partnerships and collaborations to enhance production capabilities and expand its market reach within South America, thereby solidifying its competitive advantage in the region.Bluebird Bio is another significant contender in the South America Gene Therapy Market, recognized for its innovative approaches to addressing genetic disorders through its proprietary gene therapy technologies. The company's key products are designed to target diseases that are often neglected but have a considerable impact on patient quality of life. Bluebird Bio has a strong presence in South America, emphasizing the importance of accessibility and affordability of its therapies.  The company has also engaged in strategic mergers and acquisitions to bolster its product pipeline and expand its operational footprint, ensuring that it remains competitive in this fast-paced environment. By focusing on collaboration with regional healthcare providers and regulatory bodies, Bluebird Bio aims to enhance its market position and deliver transformative gene therapies to patients throughout South America. **Key Companies in the South America Gene Therapy Market Include** **South America Gene Therapy Market Industry Developments** Recent developments in the South America Gene Therapy Market have been noteworthy, with several companies making significant strides. Amgen and Pfizer have been actively involved in Research and Development initiatives to enhance gene therapies for various genetic disorders. Bluebird Bio has also been expanding its collaborations within the region to increase access to its innovative therapies. A significant acquisition was reported in July 2023, when Novartis acquired an emerging biotech firm specializing in gene therapy, thereby strengthening its position in the Latin American market. The impact of these advancements is evident, as there has been a marked growth in market valuation, driven by increased investment and public-private partnerships.  For instance, Roche and Genentech are establishing new facilities in Brazil to foster local manufacturing capabilities, thereby improving patient access. Trends indicate a growing acceptance and demand for gene therapies across South America, reflecting a shift in healthcare investment priorities. Over the past two years, regulatory bodies have been working diligently to streamline approval processes for novel gene therapies, which has been critical in expediting treatment availability for rare genetic conditions throughout the region. **South America Gene Therapy Market Segmentation Insights** **Gene Therapy Market Therapeutic Area****Outlook** **Gene Therapy Market Technology****Outlook** **Gene Therapy Market Application****Outlook** **Gene Therapy Market Route of Administration****Outlook** **Gene Therapy Market Regional****Outlook** ## Market Drivers ### Government Initiatives and Funding Government initiatives aimed at promoting biotechnology and gene therapy research are pivotal in shaping the gene therapy market in South America. Various countries in the region have established funding programs and grants to support innovative research projects. For instance, Brazil's National Council for Scientific and Technological Development has allocated substantial resources to biotechnology, including gene therapy. This financial backing not only encourages academic institutions and private companies to engage in gene therapy research but also fosters collaboration between public and private sectors. As a result, the availability of funding is expected to enhance the development of novel gene therapies, ultimately benefiting patients and healthcare providers alike. ### Rising Prevalence of Genetic Disorders The increasing incidence of genetic disorders in South America is a crucial driver for the gene therapy market. Conditions such as cystic fibrosis, hemophilia, and muscular dystrophy are becoming more prevalent, necessitating innovative treatment options. According to health statistics, genetic disorders affect approximately 1 in 200 births in the region, highlighting a significant patient population in need of advanced therapies. This growing demand for effective treatments is likely to propel investments in gene therapy research and development, as healthcare providers seek to address these unmet medical needs. Furthermore, the rising burden of genetic diseases places additional pressure on healthcare systems, prompting governments and private entities to explore gene therapy solutions as a viable alternative to traditional treatments. ### Technological Advancements in Gene Editing Technological advancements in gene editing techniques, such as CRISPR-Cas9, are transforming the landscape of the gene therapy market in South America. These innovations enable precise modifications to genetic material, offering new avenues for treating genetic disorders. The accessibility of these technologies is increasing, with several research institutions in South America adopting them for therapeutic applications. As a result, the cost of developing gene therapies is likely to decrease, making them more accessible to a broader patient population. Moreover, the potential for personalized medicine through gene editing could lead to more effective treatments, further driving the growth of the gene therapy market in the region. ### Increasing Demand for Personalized Medicine The growing demand for personalized medicine is reshaping the gene therapy market in South America. Patients are increasingly seeking tailored treatment options that address their unique genetic profiles. This trend is prompting healthcare providers to explore gene therapies that can be customized to individual patients, enhancing treatment efficacy. The rise of genomic sequencing technologies has made it feasible to identify specific genetic mutations, paving the way for targeted gene therapies. As a result, the market for personalized gene therapies is likely to expand, driven by both patient demand and advancements in genetic research. This shift towards personalized medicine is expected to play a crucial role in the future of the gene therapy market in the region. ### Collaborations Between Academia and Industry Collaborations between academic institutions and industry players are emerging as a significant driver for the gene therapy market in South America. These partnerships facilitate the exchange of knowledge, resources, and expertise, accelerating the development of innovative gene therapies. Universities are increasingly partnering with biotech companies to translate research findings into clinical applications. This synergy not only enhances the research capabilities of academic institutions but also provides industry players with access to cutting-edge scientific discoveries. As a result, the number of clinical trials and new gene therapy products entering the market is expected to rise, contributing to the overall growth of the gene therapy market in the region. ## Future Outlook The [Gene Therapy Market](https://www.marketresearchfuture.com/reports/gene-therapy-market-8399) in South America is projected to grow at a 3.73% CAGR from 2025 to 2035, driven by technological advancements and increasing healthcare investments. **New opportunities:** - Development of localized gene therapy manufacturing facilities - Partnerships with biotech firms for innovative treatment solutions - Expansion of telehealth services for patient monitoring and support By 2035, the market is expected to achieve substantial growth and innovation. ## Segment Insights ### By Vector Type: Viral Vector (Largest) vs. Non-Viral Vector (Fastest-Growing) In the South America gene therapy market, the segment is dominated by viral vectors, accounting for a significant market share. Their established efficacy in delivering therapeutic genes has made them a preferred choice for many therapies. Non-viral vectors, while currently holding a smaller share, are rapidly gaining traction due to advancements in technology and a growing demand for safer delivery methods. The growth trends for these vector types indicate a shift towards non-viral vectors, which are expected to witness the fastest growth in the coming years. Factors driving this trend include the increasing focus on developing safer therapeutic options and the rising prevalence of genetic disorders that necessitate innovative treatment solutions. The flexibility and cost-effectiveness of non-viral vectors further enhance their appeal among developers and researchers alike. Vector Type: Viral Vector (Dominant) vs. Non-Viral Vector (Emerging) Viral vectors have established themselves as the dominant force in the gene therapy market due to their high efficiency in gene delivery and well-understood mechanisms. They are utilized in various applications, particularly in treatments for genetic diseases and cancers. Conversely, non-viral vectors are emerging as a viable alternative, heralded for their safety profile and lower immunogenicity. As research continues, non-viral vectors are expected to leverage innovations such as improved delivery systems, making them increasingly attractive in clinical settings. This dynamic between established viral vectors and the rising potential of non-viral alternatives reshapes the landscape of gene therapy, with ongoing advancements poised to influence treatment paradigms significantly. ### By Gene Type: Antigen (Largest) vs. Cytokine (Fastest-Growing) The market for gene types in the South America gene therapy sector is characterized by a significant distribution among various segment values, led by Antigen, which holds the largest market share due to its widespread applicability across therapeutic areas. Other notable segments include Cytokine, Tumor Suppressor, and Growth Factors, each contributing to the overall growth but with varying degrees of acceptance and application in therapies. Growth trends in this segment are primarily driven by the increasing prevalence of genetic disorders and the rising demand for targeted therapies. The Antigen segment continues to dominate because of its established technology and trusted efficacy. Meanwhile, Cytokine is rapidly emerging, propelled by its potential in treating severe infections and autoimmune diseases, reflecting the dynamic landscape of gene therapy innovations in the region. Antigen (Dominant) vs. Cytokine (Emerging) The Antigen segment is established as the dominant player in the South America gene therapy market, known for its versatility in addressing a myriad of diseases, fostering significant trust among healthcare professionals. Its ability to trigger immune responses makes it vital for therapeutic developments. Conversely, the Cytokine segment represents an emerging force, characterized by its innovative approaches to modulating immune responses and gaining traction among physicians. The surge in confirmed autoimmune diseases and the push for more personalized therapies position Cytokine as a pivotal component in future gene therapy strategies, reflecting the market's evolving demands and focus on efficacy. ### By Application: Oncological Disorders (Largest) vs. Rare Diseases (Fastest-Growing) The application segment of the market is primarily dominated by oncological disorders, which capture the largest share due to the rising prevalence of cancer in the region. This growing concern has led to increased investments and research in gene therapies specifically aimed at treating various types of cancers. In contrast, rare diseases, while currently smaller in market share, are emerging rapidly as developers focus on niche solutions that address unmet medical needs and leverage breakthroughs in gene therapy technologies. Growth trends in the application segment reflect a shift towards personalized medicine, especially in oncological therapies, driven by advancements in genomic research and the increasing understanding of cancer biology. Rare diseases are expected to see substantial growth due to regulatory support for orphan drugs and incentives for companies that develop gene-based treatments. The accelerating pace of clinical trials and partnerships between biotechnology firms and research institutions further bolster this trend, indicating a vibrant future for both segments in the market. Oncological Disorders: Dominant vs. Rare Diseases: Emerging Oncological disorders stand as the dominant application within the segment, reflecting a substantial focus on targeted therapies that utilize gene editing and other innovative technologies to combat cancer. The extensive prevalence of various cancers fuels demand, encouraging pharmaceutical companies to invest heavily in research and development. Conversely, rare diseases represent an emerging segment, characterized by innovative therapies that often address conditions with limited treatment options. The increasing recognition of rare diseases by governments and regulatory bodies has led to favorable policies that incentivize development, creating a promising landscape for gene therapies aimed at these conditions. Both segments illustrate the dynamic nature of the market as they cater to significant health challenges. ### By Delivery Method: In Vivo Gene Therapy (Largest) vs. Ex Vivo Gene Therapy (Fastest-Growing) The South America gene therapy market demonstrates a clear preference for In Vivo Gene Therapy, which commands a significant share due to its direct approach in treating genetic disorders. This method delivers therapeutic genes directly to the desired target cells within the body, thereby providing higher efficacy and convenience. Meanwhile, Ex Vivo Gene Therapy is garnering attention as an innovative approach, promising a substantial share in upcoming years as more clinical trials yield positive results and applications expand. Growth trends reveal that the market is rapidly evolving, with Ex Vivo Gene Therapy emerging as the fastest-growing segment. This growth is driven by technological advancements, increased research funding, and a rising number of successful clinical trials. Additionally, the growing prevalence of genetic disorders amplifies demand for effective therapies, further motivating investments in both delivery methods, each demonstrating unique advantages within the therapeutic landscape. Gene Therapy: In Vivo (Dominant) vs. Ex Vivo (Emerging) In Vivo Gene Therapy stands as the dominant method in the market, characterized by its direct administration of therapeutic genes to patients, which often results in immediate effects and improved treatment compliance. This approach is particularly effective for certain genetic disorders and allows for a wide range of applications in various therapeutic areas. Conversely, Ex Vivo Gene Therapy is recognized as an emerging technique, involving the modification of cells outside the body before reintroducing them to the patient. This method is gaining traction due to its specificity and the ability to target complex diseases, driven by advancements in genetic engineering and cell manipulation technologies. As research progresses, both methods are likely to coexist, addressing distinct therapeutic needs. ## Regional Market Share Analysis ### Brazil : Strong Growth and Innovation Hub Brazil holds a dominant position in the South American gene therapy market, accounting for 250.0 million, representing a significant market share. Key growth drivers include increasing investments in biotechnology, favorable government policies, and a rising prevalence of genetic disorders. The Brazilian government has initiated several programs to support research and development in gene therapy, enhancing infrastructure and industrial capabilities in this sector. Demand trends indicate a growing acceptance of advanced therapies among healthcare providers and patients, driven by improved healthcare access and education. ### Mexico : Innovative Approaches in Healthcare Mexico's gene therapy market is valued at 150.0 million, showcasing a robust growth trajectory. The market is driven by increasing healthcare expenditure, a rising number of clinical trials, and partnerships with international biotech firms. Regulatory bodies are streamlining approval processes for gene therapies, fostering a conducive environment for innovation. The demand for personalized medicine is also on the rise, reflecting changing consumption patterns among patients and healthcare providers. ### Argentina : Focus on Rare Diseases and Innovation Argentina's gene therapy market is valued at 100.0 million, with a steady growth outlook. The country is focusing on addressing rare diseases through innovative therapies, supported by government initiatives aimed at enhancing healthcare access. Regulatory frameworks are evolving to accommodate new therapies, which is crucial for market expansion. The demand for gene therapies is increasing, particularly in urban areas where healthcare infrastructure is more developed, leading to higher consumption rates. ### Rest of South America : Regional Variations and Growth Potential The Rest of South America holds a gene therapy market value of 112.0 million, characterized by diverse opportunities across various countries. Growth is driven by increasing healthcare investments and collaborations with global biotech companies. Regulatory environments vary, with some countries adopting more progressive policies to facilitate gene therapy approvals. Demand is rising in urban centers, where healthcare access is improving, leading to a shift in consumption patterns towards advanced therapies. ## Competitive Benchmarking The gene therapy market in South America is characterized by a dynamic competitive landscape, driven by advancements in technology and increasing investment in research and development. Major players such as Novartis (CH), Gilead Sciences (US), and Bristol-Myers Squibb (US) are actively engaged in innovative strategies that emphasize regional expansion and partnerships. Novartis (CH) has focused on enhancing its portfolio through strategic collaborations, which appear to bolster its market presence. Meanwhile, Gilead Sciences (US) is concentrating on developing therapies for rare diseases, indicating a targeted approach that may enhance its competitive edge. Collectively, these strategies contribute to a competitive environment that is increasingly characterized by innovation and collaboration. Key business tactics within this market include localizing manufacturing and optimizing supply chains to enhance efficiency and reduce costs. The competitive structure of the gene therapy market in South America is moderately fragmented, with several key players exerting influence. This fragmentation allows for a diverse range of therapeutic options, although it also necessitates that companies remain agile and responsive to market demands. In October 2025, Novartis (CH) announced a partnership with a local biotech firm to develop gene therapies tailored for South American populations. This strategic move is likely to enhance Novartis's ability to address specific regional health challenges, thereby solidifying its market position. Such collaborations may also facilitate faster regulatory approvals and market entry, which are critical in the rapidly evolving landscape of gene therapy. In September 2025, Gilead Sciences (US) launched a new gene therapy aimed at treating a rare genetic disorder prevalent in South America. This initiative not only underscores Gilead's commitment to addressing unmet medical needs but also positions the company as a leader in the region's gene therapy sector. The introduction of this therapy could potentially capture significant market share, particularly among patients seeking innovative treatment options. In August 2025, Bristol-Myers Squibb (US) expanded its clinical trials for a novel gene therapy in Brazil, focusing on a specific demographic that has been historically underserved. This expansion reflects a strategic emphasis on inclusivity and accessibility, which may enhance the company's reputation and foster patient trust. By prioritizing diverse patient populations, Bristol-Myers Squibb is likely to strengthen its competitive stance in the market. As of November 2025, current trends in the gene therapy market include a pronounced shift towards digitalization and the integration of artificial intelligence in research and development processes. Strategic alliances are increasingly shaping the competitive landscape, allowing companies to pool resources and expertise. Looking ahead, it appears that competitive differentiation will evolve from traditional price-based competition to a focus on innovation, technological advancements, and supply chain reliability. This shift may redefine how companies position themselves in the market, emphasizing the importance of sustainable practices and cutting-edge solutions. ## Recent News & Developments Recent developments in the South America Gene Therapy Market have been noteworthy, with several companies making significant strides. Amgen and Pfizer have been actively involved in Research and Development initiatives to enhance gene therapies for various genetic disorders. Bluebird Bio has also been expanding its collaborations within the region to increase access to its innovative therapies. A significant acquisition was reported in July 2023, when Novartis acquired an emerging biotech firm specializing in gene therapy, thereby strengthening its position in the Latin American market. The impact of these advancements is evident, as there has been a marked growth in market valuation, driven by increased investment and public-private partnerships.  For instance, Roche and Genentech are establishing new facilities in Brazil to foster local manufacturing capabilities, thereby improving patient access. Trends indicate a growing acceptance and demand for gene therapies across South America, reflecting a shift in healthcare investment priorities. Over the past two years, regulatory bodies have been working diligently to streamline approval processes for novel gene therapies, which has been critical in expediting treatment availability for rare genetic conditions throughout the region. ## Report Scope | MARKET SIZE 2024 | 612.0(USD Million) | | --- | --- | | MARKET SIZE 2025 | 634.83(USD Million) | | MARKET SIZE 2035 | 916.0(USD Million) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 3.73% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Million | | Key Companies Profiled | Novartis (CH), Gilead Sciences (US), Sangamo Therapeutics (US), Bluebird Bio (US), Spark Therapeutics (US), CRISPR Therapeutics (CH), Bristol-Myers Squibb (US), Roche (CH), AstraZeneca (GB) | | Segments Covered | Vector Type, Gene Type, Application, Delivery Method | | Key Market Opportunities | Emerging gene therapies targeting rare genetic disorders present substantial growth potential in the gene therapy market. | | Key Market Dynamics | Growing investment in Research and Development drives innovation in gene therapy across South America. | | Countries Covered | Brazil, Mexico, Argentina, Rest of South America | ## Frequently Asked Questions **Q: What is the projected market valuation for the South America gene therapy market by 2035?** A: The projected market valuation for the South America gene therapy market is $916.0 Million by 2035. **Q: What was the market valuation for the South America gene therapy market in 2024?** A: The market valuation for the South America gene therapy market was $612.0 Million in 2024. **Q: What is the expected CAGR for the South America gene therapy market during the forecast period 2025 - 2035?** A: The expected CAGR for the South America gene therapy market during the forecast period 2025 - 2035 is 3.73%. **Q: Which companies are considered key players in the South America gene therapy market?** A: Key players in the South America gene therapy market include Novartis, Gilead Sciences, Sangamo Therapeutics, Bluebird Bio, Spark Therapeutics, CRISPR Therapeutics, Bristol-Myers Squibb, Roche, and AstraZeneca. **Q: What are the market segments for vector type in the South America gene therapy market?** A: The market segments for vector type include Viral Vector, valued at $540.0 Million, and Non-Viral Vector, valued at $376.0 Million. **Q: What is the valuation for the application segment focusing on oncological disorders in the South America gene therapy market?** A: The valuation for the application segment focusing on oncological disorders is $182.4 Million. **Q: How does the valuation for rare diseases compare to other applications in the South America gene therapy market?** A: The valuation for rare diseases is $270.6 Million, which is higher than other applications such as cardiovascular diseases at $90.0 Million. **Q: What are the delivery methods utilized in the South America gene therapy market?** A: The delivery methods utilized in the South America gene therapy market include In Vivo Gene Therapy, valued at $366.0 Million, and Ex Vivo Gene Therapy, valued at $550.0 Million. **Q: What is the valuation for the gene type segment focusing on tumor suppressors in the South America gene therapy market?** A: The valuation for the gene type segment focusing on tumor suppressors is $91.6 Million. **Q: What does the growth trend indicate for the South America gene therapy market in the coming years?** A: The growth trend indicates a steady increase in the South America gene therapy market, with a projected valuation reaching $916.0 Million by 2035. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/south-america-gene-therapy-market-53265*